Bamboo Therapeutics Overview

  • Founded
  • 2014

Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $645M

Bamboo Therapeutics General Information

Description

Developer of gene therapies for the treatment of monogenic disorders. The company specializes in developing therapeutic reagents to diagnose diseases related to central nervous system and neuromuscular conditions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Primary Office
  • 870 Martin Luther King Jr Boulevard
  • Chapel Hill, NC 27514
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bamboo Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Aug-2016 $645M 000.00 00000 Completed Startup
1. Early Stage VC 11-Feb-2016 000.00 000.00 Completed Startup
To view Bamboo Therapeutics’s complete valuation and funding history, request access »

Bamboo Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene therapies for the treatment of monogenic disorders. The company specializes in developing therapeutic
Biotechnology
Chapel Hill, NC
000.00
0000 0000-00-00
000000&0 000.00

000000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000000000000
Rockville, MD
000 As of 0000
00000
000000000 00000

000000

d do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad mini
00000000000 0000000
Vancouver, Canada
00 As of 0000
000.00
0000 0000-00-00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bamboo Therapeutics Competitors (27)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD 000 00000 000000000 00000
000000 0000000000 Formerly VC-backed Vancouver, Canada 00 000.00 00000000 000.00
00000000 000000000 Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
000000000 Corporation Melbourne, Australia 00 00000 000000000 00000
0000000 0000000 00 Corporation Alachua, FL 000 00000 000000000000 00000
You’re viewing 5 of 27 competitors. Get the full list »

Bamboo Therapeutics Patents

Bamboo Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017281983-B2 Optimized mini-dystrophin genes and expression cassettes and their use Active 21-Jun-2016 00000000000 0
AU-2017281983-A1 Optimized mini-dystrophin genes and expression cassettes and their use Active 21-Jun-2016 00000000000
JP-6793758-B2 Optimized mini-dystrophin genes and expression cassettes and their use Active 21-Jun-2016 00000000000
JP-2021045136-A Optimized mini-dystrophin gene and expression cassette and their use Active 21-Jun-2016 00000000000 0
US-20170368198-A1 Optimized mini-dystrophin genes and expression cassettes and their use Inactive 21-Jun-2016 A61K38/1709
To view Bamboo Therapeutics’s complete patent history, request access »

Bamboo Therapeutics Executive Team (11)

Name Title Board Seat Contact Info
Xiao Xiao Ph.D Co-Founder
You’re viewing 1 of 11 executive team members. Get the full list »

Bamboo Therapeutics Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CureDuchenne Ventures Corporate Venture Capital Minority 000 0000 000000 0
To view Bamboo Therapeutics’s complete investors history, request access »

Bamboo Therapeutics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 00 08-Jan-2016 000000000 Buildings and Property 0000000 0
To view Bamboo Therapeutics’s complete investments history, request access »